Zhong-Wu Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8828010/publications.pdf

Version: 2024-02-01

105 papers	2,579 citations	27 h-index	243625 44 g-index
117	117 docs citations	117	4555
all docs		times ranked	citing authors

#	Article	IF	Citations
1	A proteomic landscape of diffuse-type gastric cancer. Nature Communications, 2018, 9, 1012.	12.8	175
2	Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Research, 2016, 26, 103-118.	12.0	129
3	Autophagy inhibition enhances PD-L1 expression in gastric cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 140.	8.6	104
4	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	7.0	80
5	Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death and Disease, 2018, 9, 123.	6.3	76
6	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq0 0 0 rgE	3T <u>/O</u> verlo	ck 10 Tf 50 54
7	Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports, 2015, 5, 8542.	3.3	66
8	Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clinical Cancer Research, 2020, 26, 2337-2345.	7.0	66
9	Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer, 2019, 22, 1183-1192.	5.3	64
10	HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. European Journal of Cancer, 2018, 88, 92-100.	2.8	64
11	Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Science Advances, 2020, 6, eaay4211.	10.3	60
12	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189.	2.0	58
13	Predicting Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Using Deep Learning of Diffusion Kurtosis MRI. Radiology, 2020, 296, 56-64.	7.3	57
14	Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer. Nature Communications, 2019, 10, 2037.	12.8	55
15	miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget, 2016, 7, 4817-4828.	1.8	54
16	Circulating tumor <scp>DNA</scp> functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Science, 2017, 108, 1881-1887.	3.9	51
17	CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. Journal of Translational Medicine, 2017, 15, 127.	4.4	45
18	Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Diagnostic Pathology, 2018, 13, 30.	2.0	43

#	Article	IF	Citations
19	Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. Breast Cancer Research, 2019, 21, 89.	5.0	41
20	Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Science Translational Medicine, $2020,12,.$	12.4	39
21	Identification and Validation of Plasma Metabolomic Signatures in Precancerous Gastric Lesions That Progress to Cancer. JAMA Network Open, 2021, 4, e2114186.	5.9	38
22	Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Journal of Experimental and Clinical Cancer Research, 2018, 37, 129.	8.6	37
23	Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA <i>in situ</i> hybridization and its clinical significance. Oncotarget, 2016, 7, 39671-39679.	1.8	37
24	Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Cancer Letters, 2018, 419, 64-74.	7.2	35
25	The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. Scientific Reports, 2015, 5, 9447.	3.3	34
26	Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. Journal of Hematology and Oncology, 2018, 11, 20.	17.0	32
27	In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 779-787.	2.8	30
28	Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers. Pathology and Oncology Research, 2020, 26, 2577-2585.	1.9	30
29	Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary. American Journal of Surgical Pathology, 2018, 42, 160-171.	3.7	29
30	Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. Journal of Translational Medicine, 2018, 16, 15.	4.4	29
31	BMP-2 enhances the migration and proliferation of hypoxia-induced VSMCs via actin cytoskeleton, CD44 and matrix metalloproteinase linkage. Experimental Cell Research, 2018, 368, 248-257.	2.6	28
32	Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer, 2015, 15, 894.	2.6	27
33	Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer, 2015, 15, 6.	2.6	27
34	Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis., 2022, 10, e003984.		27
35	Evaluation of the prognostic value of the metastatic lymph node ratio for gastric cancer. American Journal of Surgery, 2014, 207, 555-565.	1.8	25
36	Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PLoS ONE, 2016, 11, e0156659.	2.5	25

3

#	Article	IF	CITATIONS
37	PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. Diagnostic Pathology, 2017, 12, 72.	2.0	25
38	Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment., 2020, 8, e001297.		25
39	Combination of microtubule associated protein-tau and \hat{I}^2 -tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. European Journal of Cancer, 2014, 50, 2328-2335.	2.8	24
40	Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. Journal of Hematology and Oncology, 2018, 11, 109.	17.0	22
41	Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing. American Journal of Cancer Research, 2017, 7, 1540-1553.	1.4	21
42	Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics, 2015, 14, 2634-2641.	4.1	20
43	EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2â€mediated MAPK pathway activation in gastric cancer cells and avatar mice. International Journal of Cancer, 2019, 145, 2440-2449.	5.1	20
44	Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach. Oncogene, 2021, 40, 5705-5717.	5.9	20
45	<i>ABCC2</i> -24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget, 2016, 7, 55449-55457.	1.8	20
46	GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15. Diagnostic Pathology, 2017, 12, 51.	2.0	19
47	Lysyl oxidase assists tumorâ€ʻinitiating cells to enhance angiogenesis in hepatocellular carcinoma. International Journal of Oncology, 2019, 54, 1398-1408.	3.3	19
48	Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. BioMed Research International, 2018, 2018, 1-10.	1.9	18
49	Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: Novel evidence for extended surgery and a tumor grading system. BioScience Trends, 2018, 12, 185-192.	3.4	17
50	The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis. BMC Cancer, 2020, 20, 671.	2.6	17
51	Pyrotinib combined with CDK4/6 inhibitor in HER2â€positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. Clinical and Translational Medicine, 2020, 10, e148.	4.0	17
52	Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer. EBioMedicine, 2021, 74, 103714.	6.1	17
53	Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death and Disease, 2019, 10, 139.	6.3	16
54	SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors. International Journal of Clinical and Experimental Pathology, 2015, 8, 7072-82.	0.5	16

#	Article	IF	CITATIONS
55	SATB2 Shows Different Profiles Between Appendiceal Adenocarcinomas Ex Goblet Cell Carcinoids and Appendiceal/Colorectal Conventional Adenocarcinomas: An Immunohistochemical Study With Comparison to CDX2. Gastroenterology Research, 2018, 11, 221-230.	1.3	14
56	Organ-preserving surgery for locally advanced duodenal gastrointestinal stromal tumor after neoadjuvant treatment. BioScience Trends, 2017 , 11 , $483-489$.	3.4	13
57	Use of 18F-FDG-PET/CT for Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas. Contrast Media and Molecular Imaging, 2018, 2018, 1-8.	0.8	13
58	Clinicopathological and Immunomicroenvironment Characteristics of Epstein–Barr Virus-Associated Gastric Cancer in a Chinese Population. Frontiers in Oncology, 2020, 10, 586752.	2.8	13
59	Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors. PLoS ONE, 2016, 11, e0154679.	2.5	12
60	Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer. British Journal of Cancer, 2020, 123, 973-981.	6.4	12
61	Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer. Diagnostic Pathology, 2021, 16, 38.	2.0	12
62	Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways. Journal of Translational Medicine, 2017, 15, 253.	4.4	11
63	Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget, 2016, 7, 30241-30249.	1.8	11
64	miR-34a increases the sensitivity of colorectal cancer cells to 5-fluorouracil and. American Journal of Cancer Research, 2018, 8, 280-290.	1.4	11
65	Pattern and Management of Recurrence of Mid-Low Rectal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases. Clinical Colorectal Cancer, 2018, 17, e307-e313.	2.3	10
66	An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer. Oncolmmunology, 2020, 9, 1792038.	4.6	10
67	Molecular characteristics of synchronous multiple gastric cancer. Theranostics, 2020, 10, 5489-5500.	10.0	10
68	Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma andÂTheirÂPrognostic Impacts. Molecular and Cellular Proteomics, 2021, 20, 100015.	3.8	10
69	From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression. Frontiers in Pharmacology, 2021, 12, 757994.	3.5	10
70	The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma. BioMed Research International, 2017, 2017, 1-12.	1.9	9
71	Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. Theranostics, 2019, 9, 3485-3500.	10.0	9
72	Diagnostic value of negative enrichment and immune fluorescence in situ hybridization for intraperitoneal free cancer cells of gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 945-954.	2.2	9

#	Article	IF	Citations
73	Up-Regulation of SALL4 Is Associated With Survival and Progression via Putative WNT Pathway in Gastric Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 600344.	3.7	8
74	PKUCH 04 trial: Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR/MSS locally advanced middle to low rectal cancer Journal of Clinical Oncology, 2022, 40, 3609-3609.	1.6	8
75	Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells. Journal of Cancer Research and Clinical Oncology, 2017, 143, 639-648.	2.5	7
76	<p>Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models</p> . Cancer Management and Research, 2019, Volume 11, 1349-1362.	1.9	7
77	Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications. Annals of Translational Medicine, 2021, 9, 967-967.	1.7	7
78	RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 677826.	2.8	7
79	Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors. American Journal of Cancer Research, 2020, 10, 249-262.	1.4	7
80	Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. Radiation Oncology, 2022, 17, 45.	2.7	7
81	Four-color fluorescence in-situ hybridization is useful to assist to distinguish early stage acral and cutaneous melanomas from dysplastic junctional or compound nevus. Diagnostic Pathology, 2020, 15, 51.	2.0	6
82	Virtual bronchoscopic navigation without fluoroscopy guidance for peripheral pulmonary lesions in inexperienced pulmonologist. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 530-539.	2.2	6
83	The Value of Perioperative Chemotherapy for Patients With Hepatoid Adenocarcinoma of the Stomach Undergoing Radical Gastrectomy. Frontiers in Oncology, 2021, 11, 789104.	2.8	6
84	The correlation between molecular pathological profiles and metabolic parameters of 18F-FDG PET/CT in patients with gastroesophageal junction cancer. Abdominal Radiology, 2020, 45, 312-321.	2.1	5
85	Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas. Diagnostic Pathology, 2021, 16, 78.	2.0	5
86	PTP4A3 Is a Prognostic Biomarker Correlated With Immune Infiltrates in Papillary Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 717688.	4.8	5
87	Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma. Oncotarget, 2017, 8, 108146-108155.	1.8	5
88	Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer. Frontiers in Oncology, 2021, 11, 708214.	2.8	5
89	Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary Cancer in Clinical Practice, 2021, 19, 7.	1.5	4
90	The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer. Frontiers in Oncology, 2021, 11, 719217.	2.8	4

#	Article	IF	CITATIONS
91	Abdominoperineal excision following preoperative radiotherapy for rectal cancer: unfavorable prognosis even with negative circumferential resection margin. World Journal of Gastroenterology, 2014, 20, 9138-45.	3.3	3
92	Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients. Npj Breast Cancer, 2022, 8, 52.	5.2	3
93	Genetic alteration of Chinese patients with rectal mucosal melanoma. BMC Cancer, 2021, 21, 623.	2.6	2
94	A 18FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 632-640.	2.2	2
95	Epstein–Barr virus-associated gastric adenosquamous carcinoma with concurrent gastric carcinoma with lymphoid stroma: a case report and review of the literature. BMC Gastroenterology, 2022, 22, .	2.0	2
96	Fat clearance and conventional fixation identified ypN0 rectal cancers following intermediate neoadjuvant radiotherapy have similar long-term outcomes. World Journal of Gastrointestinal Oncology, 2019, 11, 877-886.	2.0	1
97	Identification of "regulation of RhoA activity panel―as a prognostic and predictive biomarker for gastric cancer. Aging, 2021, 13, 714-734.	3.1	1
98	MRI measurements predict major low anterior resection syndrome in rectal cancer patients. International Journal of Colorectal Disease, 2022, 37, 1239-1249.	2.2	1
99	Compliance and safety of neoadjuvant intensity modulated radiotherapy (IMRT) with concurrent capecitabine for locally advanced rectal cancer: Updated results from a phase II trial (ChiCTR-TNC-10001094) Journal of Clinical Oncology, 2014, 32, 3598-3598.	1.6	0
100	The pathway regulating RhoA activity to predict the survival of gastric cancers Journal of Clinical Oncology, 2018, 36, 49-49.	1.6	0
101	SPANOM: A cost-effective method of detecting MSI in ctDNA Journal of Clinical Oncology, 2018, 36, e24263-e24263.	1.6	0
102	CANO17, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker. American Journal of Cancer Research, 2021, 11, 1697-1708.	1.4	0
103	Automated assessment of DNA ploidy, chromatin organization, and stroma fraction to predict prognosis and adjuvant therapy response in patients with stage II colorectal carcinoma American Journal of Cancer Research, 2021, 11, 6119-6132.	1.4	0
104	Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for patients with pMMR, high-risk, and locally advanced middle to low rectal cancer Journal of Clinical Oncology, 2022, 40, 3611-3611.	1.6	0
105	The drug targets genomic alterations detected in female tumor tissue with melanoma Journal of Clinical Oncology, 2022, 40, e21558-e21558.	1.6	O